SCHEMBL771656

SCHEMBL771656

O=C(CCC(=O)N1CCC2CCCC=C2C1)N1CCC2CCCC=C2C1

nearest known ligand 0.38

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MAPK1 P28482 2/20 0.36
ALDH1A1 P00352 2/20 0.35
POLB P06746 2/20 0.35
SMN1; SMN2 Q16637 2/20 0.35
KMT2A Q03164 1/20 0.35
HRH3 Q9Y5N1 3/20 0.35
NPC1 O15118 1/20 0.34
PDE4B Q07343 1/20 0.34
MCHR1 Q99705 1/20 0.33
LMNA P02545 1/20 0.33
MAPT P10636 1/20 0.33
HPGD P15428 1/20 0.33
HTT P42858 1/20 0.33
NAMPT P43490 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL771900 0.94 ATM (0.39) ALDH1A1SMN1; SMN2KMT2ANPC1HPGD
SCHEMBL770696 0.94 MEN1 (0.38) MAPK1ALDH1A1POLBSMN1; SMN2KMT2A
SCHEMBL770401 0.94 LMNA (0.39) MAPK1ALDH1A1SMN1; SMN2KMT2ANPC1
SCHEMBL769789 0.94 NPC1 (0.42) MAPK1ALDH1A1POLBSMN1; SMN2KMT2A
SCHEMBL769773 0.93 HDAC3 (0.35) MAPK1ALDH1A1POLBSMN1; SMN2NPC1
SCHEMBL770939 0.92 NPC1 (0.49) ALDH1A1SMN1; SMN2KMT2ANPC1LMNA
SCHEMBL770744 0.91 SMYD3 (0.37) MAPK1ALDH1A1POLBSMN1; SMN2LMNA
SCHEMBL771910 0.91 ALDH1A1 (0.42) MAPK1ALDH1A1POLBSMN1; SMN2KMT2A
SCHEMBL770448 0.91 SMN1; SMN2 (0.44) ALDH1A1SMN1; SMN2KMT2AHRH3NPC1
SCHEMBL770204 0.90 HDAC3 (0.42) MAPK1ALDH1A1POLBSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8822452-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2014-09-02 US disclosed
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2013-11-14 US disclosed
US-8524894-B2 Inhibitor compounds of 11-beta-hydroxysteroid dehydrogenase type 1 LABORATORIOS SALVAT, S.A. (ES) 2013-09-03 US disclosed
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 LABORATORIOS SALVAT, S.A. (ES) 2012-03-22 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130303522-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 401/4885ALDH1A1 144/4885POLB 375/4885
US-20120071466-A1 INHIBITOR COMPOUNDS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 MAPK1 410/4885ALDH1A1 142/4885POLB 358/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.